181 related articles for article (PubMed ID: 37141553)
21. Development of new therapeutic options for the treatment of uveal melanoma.
Wang JZ; Lin V; Toumi E; Wang K; Zhu H; Conway RM; Madigan MC; Murray M; Cherepanoff S; Zhou F; Shu W
FEBS J; 2021 Nov; 288(21):6226-6249. PubMed ID: 33838075
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
Masaoutis C; Kokkali S; Theocharis S
Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
[TBL] [Abstract][Full Text] [Related]
23. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
24. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
25. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
26. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
27. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
28. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.
Martinez-Perez D; Viñal D; Solares I; Espinosa E; Feliu J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885078
[TBL] [Abstract][Full Text] [Related]
29. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
[TBL] [Abstract][Full Text] [Related]
30. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract][Full Text] [Related]
32. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
33. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
34. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
35. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
36. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen CL; Kött J; Hartung TI; Torster LK; Gebhardt C
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945010
[TBL] [Abstract][Full Text] [Related]
37. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
38. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
39. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
40. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]